Phase I â??II Clinical Trial on Safety, Immunogenicity and probing efficacy of the Revived Recombinant Vaccine against Human Chorionic Gonadotropin (hCG) - R-Î²hCG

Indian Council of Medical Research0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Willing to participate in the trial and sign the consent form and audio visual recording.
•2.Healthy married sexually active women (age group 22-35) who have completed their family with minimum two living children.
•3.Has ovulatory cycles
•4. Menstruating regularly
•5.Not using any hormonal contraceptive since the last 6 months
•6.Using non-hormonal IUDs or willing to use non-hormonal IUDs or who have already undergone sterilization.
•7.Women after six months of delivery with regular menstrual cycles or six weeks after Medical Termination of Pregnancy (MTP) with return of regular menstrual cycle.
•8.Resident of Delhi/NCR

•1.Women who are pregnant or suspecting pregnancy
•2.who are currently breast feeding
•3.women having â??
•i)STD, Reproductive Tract Infection (RTI) and HIV, HCV, Hepatitis B, VDRL, HBsAg infection,
•ii)Gynaecological disorders
•iii)history of recurrent abortion
•iv)history of Joint pains
•v)secondary infertility
•vi)any type of suspected cancer
•vii)allergic to any drug or food, auto-immune and endocrine disorders
•viii)known systematic disease and on chronic drug therapy i.e. hormone therapy
•ix)any psychiatric disorders
•x)BMI above 30, (obese)
•xi)PCOS (using Rotterdam Criteria)
•xii) any problem with IUDs
•4.who are currently using any other hormonal contraceptive

发起方